Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 13, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Interstitial CystitisBladder Pain Syndrome

Interventions

DRUG

VNX001

Intravesical administration of VNX001

Trial Locations (5)

RECRUITING

Georgia Urology, Cartersville

RECRUITING

Arizona Urology Specialists, Tucson

SUSPENDED

Prestige Medical Group, Tustin

SUSPENDED

Valley Urology, Inc., Fresno

RECRUITING

Oregon Urology Institute, Springfield

All Listed Sponsors

collaborator

Prevail Infoworks

INDUSTRY

lead

Vaneltix Pharma, Inc.

INDUSTRY